Friday 6 November 2026
Export SYK’s income statement to Excel — free account
Stryker Corporation
SYK Healthcare Medical Devices
Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024.
- Revenue
- +7.64%
- EPS
- −12.4%
- Free cash flow
- −19.4%
- Total debt
- −10.0%
Quarter to September 2026, against a year earlier
324.26
10.82
−3.23%
Follow SYK
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
29.14 | 32.36 | 37.64 | 41.40 |
+8 more quarters Free account |
P/S ratio |
4.00 | 4.67 | 4.98 | 5.35 | |
P/FCF ratio |
23.88 | 25.68 | 27.53 | 31.36 | |
P/Operating CF |
72.04 | 95.75 | 216.55 | 62.68 | |
P/B ratio |
4.49 | 5.03 | 5.48 | 5.99 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.45 | 5.12 | 5.44 | 5.82 | |
EV/EBITDA |
17.61 | 19.57 | 22.16 | 24.02 | |
EV/Operating CF |
21.47 | 23.93 | 25.60 | 28.96 | |
EV/FCF |
26.52 | 28.12 | 30.10 | 34.11 | |
Quick Ratio |
1.07 | 1.08 | 1.04 | 1.04 | |
Current Ratio |
2.18 | 2.16 | 2.11 | 1.89 | |
Net Debt/EBITDA |
8.77 | 5.87 | 9.51 | 5.55 | |
Debt/Assets |
31.60% | 31.17% | 31.81% | 33.15% | |
Debt/Equity |
0.64 | 0.62 | 0.64 | 0.71 | |
Asset Turnover |
0.56 | 0.55 | 0.55 | 0.55 | |
Operating CF/Net income |
1.94 | 0.99 | 0.78 | 2.52 | |
Capex/Depreciation |
(0.80) | (0.68) | (0.55) | (1.37) | |
Interest Coverage |
7.23 | 11.77 | 6.32 | 11.71 | |
Research and Development Expense of Revenue |
6.64% | 6.59% | 6.86% | 5.59% | |
Selling, General and Administrative Expense of Revenue |
35.48% | 33.83% | 37.89% | 31.06% | |
Intangible Assets out of Total Assets |
0.53 | 0.53 | 0.53 | 0.52 | |
Share Based Compensation of Revenue |
1.03% | 0.82% | 1.45% | 0.67% | |
Graham Net Nets |
(0.09) | (0.08) | (0.08) | (0.08) | |
Graham Number |
114.23 | 117.02 | 108.57 | 105.86 | |
Earnings Yield |
3.43% | 3.09% | 2.66% | 2.42% | |
Free Cash Flow Yield |
4.19% | 3.89% | 3.63% | 3.19% | |
Revenue per Share |
17.06 | 17.18 | 15.72 | 18.76 | |
Operating CF per Share |
3.82 | 3.29 | 1.52 | 5.61 | |
Capex per Share |
(0.62) | (0.53) | (0.43) | (1.13) | |
Free Cash Flow per Share |
3.20 | 2.76 | 1.08 | 4.47 | |
Cash per Share |
8.56 | 9.06 | 7.74 | 10.73 | |
Shareholders Equity per Share |
61.37 | 62.55 | 60.01 | 58.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
61.37 | 62.55 | 60.01 | 58.66 | |
Free Cash Flow |
1,224.00 | 1,059.00 | 415.00 | 1,710.00 | |
Working Capital |
7,683.00 | 7,734.00 | 7,023.00 | 6,961.00 | |
Capital Expenditures |
(237.00) | (202.00) | (166.00) | (433.00) | |
Net Current Asset Value |
(9,607.00) | (9,524.00) | (9,974.00) | (10,669.00) | |
EV/EBIT |
21.52 | 23.89 | 27.58 | 29.88 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.06 | |
Price to Operating Income |
19.37 | 21.82 | 25.22 | 27.48 | |
| Other line items | |||||
Average Receivables |
3,668.00 | 3,830.50 | 3,766.00 | 4,013.00 | |
Average Payables |
1,566.00 | 1,552.50 | 1,528.00 | 1,739.00 | |
Average Inventory |
5,558.50 | 5,405.00 | 5,262.00 | 5,042.00 | |
Average Assets |
47,152.00 | 47,130.50 | 46,148.50 | 45,407.50 | |
Average Common Equity |
22,621.00 | 22,589.50 | 21,954.50 | 21,527.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026